Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
or

Altimmune Inc (ALT)

Altimmune Inc (ALT)
3.81 x 2 4.00 x 1
Pre-market by (Cboe BZX)
4.24 -0.22 (-4.93%) 04/04/25 [NASDAQ]
3.81 x 2 4.00 x 1
Pre-market 3.78 -0.46 (-10.85%) 05:50 ET
Quote Overview for Fri, Apr 4th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
4.13
Day High
4.44
Open 4.30
Previous Close 4.46 4.46
Volume 2,987,700 2,987,700
Avg Vol 2,986,335 2,986,335
Stochastic %K 5.25% 5.25%
Weighted Alpha -60.14 -60.14
5-Day Change -1.08 (-20.30%) -1.08 (-20.30%)
52-Week Range 4.13 - 11.16 4.13 - 11.16
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 326,539
  • Shares Outstanding, K 77,014
  • Annual Sales, $ 20 K
  • Annual Income, $ -95,060 K
  • EBIT $ -103 M
  • EBITDA $ -107 M
  • 60-Month Beta 0.91
  • Price/Sales 17,174.12
  • Price/Cash Flow N/A
  • Price/Book 2.57

Options Overview Details

View History
  • Implied Volatility 120.64% ( +29.87%)
  • Historical Volatility 76.76%
  • IV Percentile 71%
  • IV Rank 35.21%
  • IV High 228.55% on 08/05/24
  • IV Low 62.00% on 02/12/25
  • Put/Call Vol Ratio 0.08
  • Today's Volume 5,659
  • Volume Avg (30-Day) 7,886
  • Put/Call OI Ratio 0.28
  • Today's Open Interest 144,092
  • Open Int (30-Day) 142,230

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.36
  • Number of Estimates 6
  • High Estimate -0.33
  • Low Estimate -0.38
  • Prior Year -0.34
  • Growth Rate Est. (year over year) -5.88%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.13 +2.66%
on 04/04/25
Period Open: 5.96
6.16 -31.17%
on 03/24/25
-1.72 (-28.86%)
since 03/04/25
3-Month
4.13 +2.66%
on 04/04/25
Period Open: 7.26
7.83 -45.85%
on 01/08/25
-3.02 (-41.60%)
since 01/03/25
52-Week
4.13 +2.66%
on 04/04/25
Period Open: 8.90
11.16 -62.01%
on 11/13/24
-4.66 (-52.36%)
since 04/04/24

Most Recent Stories

More News
Buying These Dirt-Cheap Stocks Could Be a Brilliant Move

Valuation always matters in investing. And sometimes you can find stocks that are especially great bargains.

ALT : 4.24 (-4.93%)
MRNA : 25.11 (-2.41%)
PFE : 22.97 (-5.43%)
Altimmune Shares Sink This Year, But Retail Traders See A Buyout On The Horizon

A Betaville report suggested Altimmune has begun a strategic review with an adviser, with speculation that three major pharmaceutical firms may be involved.

ALT : 4.24 (-4.93%)
VTI : 248.47 (-5.87%)
IWM : 181.19 (-4.46%)
XBI : 73.66 (-5.73%)
Altimmune to Host Virtual R&D Day on March 13, 2025

ALT : 4.24 (-4.93%)
Altimmune to Participate in the Leerink Global Healthcare Conference

ALT : 4.24 (-4.93%)
Altimmune Retail Buzz Heats Up On MASH Progress, FDA Nod For New Trials: Stock Jumps After Q4 Print

The company plans to unveil details at its virtual R&D Day on March 13.

ALT : 4.24 (-4.93%)
VTI : 248.47 (-5.87%)
IWM : 181.19 (-4.46%)
XBI : 73.66 (-5.73%)
Altimmune Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

ALT : 4.24 (-4.93%)
Seasoned Biopharmaceutical Industry Executives Teri Lawver and Jerry Durso Appointed to Altimmune Board of Directors

ALT : 4.24 (-4.93%)
Altimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025

ALT : 4.24 (-4.93%)
Altimmune to Participate in the Guggenheim SMID Cap Biotech Conference

ALT : 4.24 (-4.93%)
Why Altimmune Was Such a Robustly Healthy Stock on Thursday

Altimmune (NASDAQ: ALT) had some encouraging news to share with the world as the trading week drew near a close on Thursday. The biotech announced that it will soon ascend to an important, specialized...

ALT : 4.24 (-4.93%)

Business Summary

Altimmune, Inc. is a clinical-stage immunotherapeutics company. It focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease. The company's proprietary platform technologies consist of RespirVec and Densigen. Altimmune Inc., formerly...

See More

Key Turning Points

3rd Resistance Point 4.72
2nd Resistance Point 4.58
1st Resistance Point 4.41
Last Price 4.24
1st Support Level 4.10
2nd Support Level 3.96
3rd Support Level 3.79

See More

52-Week High 11.16
Fibonacci 61.8% 8.47
Fibonacci 50% 7.64
Fibonacci 38.2% 6.82
Last Price 4.24
52-Week Low 4.13

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trader's Cheat Sheet: Your Secret Weapon for Smarter Trades